Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Coherus Oncology (CHRS) over the last 12 years, with Q3 2025 value amounting to $3.4 million.

  • Coherus Oncology's Share-based Compensation fell 5065.52% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.6 million, marking a year-over-year decrease of 3616.22%. This contributed to the annual value of $27.8 million for FY2024, which is 3550.92% down from last year.
  • Per Coherus Oncology's latest filing, its Share-based Compensation stood at $3.4 million for Q3 2025, which was down 5065.52% from $5.4 million recorded in Q2 2025.
  • Over the past 5 years, Coherus Oncology's Share-based Compensation peaked at $16.9 million during Q1 2021, and registered a low of $3.4 million during Q3 2025.
  • Moreover, its 5-year median value for Share-based Compensation was $10.8 million (2023), whereas its average is $9.9 million.
  • Per our database at Business Quant, Coherus Oncology's Share-based Compensation surged by 7670.33% in 2021 and then plummeted by 5065.52% in 2025.
  • Quarter analysis of 5 years shows Coherus Oncology's Share-based Compensation stood at $10.9 million in 2021, then grew by 7.13% to $11.7 million in 2022, then fell by 7.91% to $10.8 million in 2023, then tumbled by 40.88% to $6.4 million in 2024, then plummeted by 46.91% to $3.4 million in 2025.
  • Its last three reported values are $3.4 million in Q3 2025, $5.4 million for Q2 2025, and $5.4 million during Q1 2025.